Ertapenem

證據等級: L5

預測適應症: 10 個

Ertapenem: From Complicated Bacterial Infections to Staphylococcus aureus Infection (Persistent MSSA Bacteremia)

One-Sentence Summary

Ertapenem (Invanz®) is a broad-spectrum 1β-methyl carbapenem antibiotic, globally established for complicated urinary tract infections, intra-abdominal infections, community-acquired pneumonia, and complicated skin/soft tissue infections — though formal Singapore HSA registration is not currently recorded in this dataset. The TxGNN model predicts it may be effective for Staphylococcus aureus Infection — specifically as a novel salvage combination partner (cefazolin + ertapenem) for persistent MSSA bacteremia — with 8 clinical trials and 20 publications supporting this direction, including a Phase 2 RCT currently recruiting.

Quick Overview

Item	Content
Original Indication	Complicated urinary tract infections, intra-abdominal infections, CAP, skin/soft tissue infections (global approvals; Singapore HSA registration not recorded in current dataset)
Predicted New Indication	Staphylococcus aureus Infection (persistent MSSA bacteremia — cefazolin + ertapenem salvage combination)
TxGNN Prediction Score	99.28%
Evidence Level	L3
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Ertapenem is a Group 1 carbapenem that inhibits bacterial cell wall synthesis by binding preferentially to penicillin-binding proteins (PBP) 1a, 1b, 2, and 3. Unlike imipenem or meropenem, it has limited activity against Pseudomonas aeruginosa and Enterococcus species. Its pharmacokinetic profile — once-daily dosing, ~4-hour half-life, ~85–95% protein binding, and significant renal excretion — makes it particularly suited to outpatient parenteral antibiotic therapy (OPAT) and community-onset infections.

The novel repurposing concept centres on the cefazolin + ertapenem (CEZ+ERT) combination for persistent methicillin-susceptible S. aureus (MSSA) bacteremia — a condition where standard antistaphylococcal monotherapy can fail due to the inoculum effect. Under high bacterial load, β-lactamase enzymes produced by S. aureus can overwhelm and inactivate cefazolin. Ertapenem acts as a competitive β-lactamase "sponge," saturating the enzyme's active site and rescuing cefazolin's bactericidal activity through complementary PBP2/PBP3 binding. Beyond this pharmacological mechanism, in vitro evidence (PMID 34978891) demonstrates that ertapenem stimulates interleukin-1β release from peripheral blood monocytes, potentially augmenting the host innate immune response — which may explain why CEZ+ERT shows markedly greater in vivo potency than would be predicted from in vitro MIC data alone.

It is critical to emphasise that this is a salvage strategy for confirmed persistent MSSA bacteremia only — not a first-line treatment, and strictly ineffective against MRSA (ertapenem has no PBP2a binding activity). Clinical case series have documented rapid bacteremia clearance in refractory endocarditis, LVAD-related infections, and neonatal MSSA sepsis. The accumulating signal has now motivated a dedicated Phase 2 RCT (NCT04886284) and a large Phase 4 study (n=2,096, NCT07376889) — indicating the infectious disease community regards this combination as a credible therapeutic hypothesis deserving rigorous prospective testing.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04886284	Phase 2	Recruiting	60	CERT trial: First dedicated RCT evaluating CEZ+ERT for persistent MSSA bacteremia; sub-study of the SNAP adaptive platform (NCT05137119); in vitro, animal, and human case series data support the hypothesis; expected completion July 2026
NCT07376889	Phase 4	Not Yet Recruiting	2,096	COMBAT-SAB: Large-scale RCT comparing combination vs single-agent antibiotic therapy for SAB; if ertapenem is included as the combination agent, this will be the most definitive validation to date; expected completion January 2029
NCT07148960	Phase 4	Enrolling by Invitation	300	SABEDTIO: Pragmatic open-label RCT evaluating early dual IV antibiotic therapy for SAB to reduce bacteremia duration (<6 days) and improve clinical outcomes; expected completion July 2027
NCT00366249	Phase 3	Completed	1,061	Tigecycline vs ertapenem for diabetic foot infections; co-primary efficacy endpoints not met; largest completed trial providing ertapenem safety and tolerability data in complicated infections including MSSA
NCT06174649	N/A	Completed	900	FAST trial: Multicenter RCT evaluating rapid phenotypic AST (Reveal™) for Gram-negative bacteremia; background context for antimicrobial stewardship decision-making around carbapenem use
NCT06044272	N/A	Completed	10,000	AMR surveillance across healthcare facilities in Meta State, Colombia (2018–2022); large-scale resistance profile data providing epidemiological context for ertapenem stewardship

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38946294	2024	Retrospective Cohort	J Antimicrob Chemother	First comparative data for carbapenem combination (CEZ or OXA + carbapenem) vs standard of care in persistent MSSA bacteraemia; provides treatment-level evidence beyond case series
40448546	2025	Retrospective Cohort	J Antimicrob Chemother	Hypoalbuminemia (albumin <2.5 g/dL) associated with suboptimal ertapenem exposures in MSSA combination therapy; critical PK/safety guidance for clinical implementation given ertapenem's high protein binding
39230345	2025	Review	Am J Health-Syst Pharm	Comprehensive review of combination treatment options for persistent MSSA bacteremia, positioning CEZ+ERT within the current salvage treatment landscape alongside daptomycin and fosfomycin-based regimens
31773134	2020	Case Series	Clin Infect Dis	CEZ+ERT salvage therapy successfully cleared 11 persistent MSSA bacteremia cases (including 6 endocarditis); immediate clearance (≤24 hours) in 8 cases; in vivo synergy confirmed in rat MSSA endocarditis model
27572414	2016	Case Series	Antimicrob Agents Chemother	Original report describing CEZ+ERT clearing refractory MSSA bacteremia; in vitro and murine skin infection model confirmed synergy; foundational publication for this combination concept
34978891	2022	Mechanistic Study	Antimicrob Agents Chemother	CEZ+ERT combination stimulates IL-1β release from peripheral blood monocytes in the presence and absence of S. aureus; ertapenem identified as the primary immune-activating driver; proposes immune augmentation as a novel mechanism explaining in vivo potency
35493130	2022	In vitro / Biofilm	Open Forum Infect Dis	ERT+CEZ demonstrates potent activity within staphylococcal biofilms, beyond what antistaphylococcal β-lactams alone achieve; mechanistically relevant for endocarditis and device-related MSSA infections
34599521	2021	Case Series	J Card Surg	CEZ+ERT used as salvage therapy for refractory LVAD-related MSSA infections prior to heart transplantation; supports applicability to device-related infections where source control is not feasible
39777519	2025	In vitro	J Infect Dis	Carbapenems (ertapenem and meropenem) enhance ceftaroline- and vancomycin-mediated killing of MRSA; extends the carbapenem combination concept beyond MSSA to drug-resistant strains
15164963	2004	RCT Subgroup Analysis	Int J Antimicrob Agents	Ertapenem vs piperacillin-tazobactam in complicated skin/soft tissue infections caused by MSSA (n=185 MSSA subgroup from Phase 3 RCT); demonstrates ertapenem's established clinical efficacy against MSSA in a randomised trial setting

Safety Considerations

Please refer to the package insert for safety information.

Key pharmacokinetic safety note relevant to this indication: Ertapenem is highly protein-bound (~85–95%). Retrospective data (PMID 40448546) advise against ertapenem use in patients with serum albumin <2.5 g/dL, where suboptimal drug exposures may compromise therapeutic effect. This is clinically critical when considering CEZ+ERT combination therapy in septic patients who frequently present with concurrent hypoalbuminemia or malnutrition.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The cefazolin + ertapenem combination has accumulated a credible and growing body of evidence — retrospective cohorts, multiple case series spanning endocarditis, LVAD infections, and neonatal sepsis, plus confirmed in vitro and animal model synergy — with a well-characterised mechanistic basis. A Phase 2 RCT is actively recruiting (NCT04886284), with results expected July 2026. This is a genuine drug repurposing signal with an actionable clinical niche as a salvage strategy, but adoption ahead of RCT results should be limited to refractory MSSA cases under specialist infectious disease guidance.

To proceed, the following is needed:

Await Phase 2 RCT results from CERT (NCT04886284, n=60, estimated completion July 2026) as the first controlled evidence for CEZ+ERT in persistent MSSA bacteremia
Confirm whether ertapenem is an active study arm in COMBAT-SAB (NCT07376889) and SABEDTIO (NCT07148960) protocols
Verify Singapore HSA registration status — ertapenem may be accessible via Therapeutic Products (Unregistered Medicinal Products) authorisation for compassionate/named-patient use even without formal HSA registration
Obtain complete safety package: Singapore/TFDA package insert with full warnings, contraindications, and drug interaction data (currently unavailable in this dataset)
Implement albumin monitoring protocol prior to CEZ+ERT initiation; avoid or seek infectious disease specialist guidance when serum albumin <2.5 g/dL
Define patient selection criteria for institutional salvage use: MSSA-confirmed (not MRSA) persistent bacteremia, failing standard antistaphylococcal therapy for ≥72 hours, appropriate source control measures undertaken
Consider institutional ethics/stewardship review for any compassionate use protocol pending RCT results
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.